Company: SRPT
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0000950170-25-029973
Chunk: 428

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-02-28
Form: 10-K
Item: Item 9A
Chunk 428
---
 (188,588
    )

    (12,521
    )

    42,557

    Increase in inventory

    (395,170
    )

    (147,714
    )

    (50,780
    )

    (Increase) decrease in other assets

    (9,676
    )

    1,808

    (27,937
    )

    Decrease in deferred revenue

    (32,160
    )

    (86,828
    )

    (89,244
    )

    Increase (decrease) in accounts payable, accrued expenses,   lease liabilities and other liabilities

    110,649

    (50,135
    )

    147,572

    Net cash used in operating activities

    (205,787
    )

    (500,993
    )

    (325,346
    )

    Cash flows from investing activities:

    Purchase of property and equipment

    (136,956
    )

    (76,106
    )

    (30,824
    )

    Purchase of available-for-sale securities

    (1,099,595
    )

    (2,044,940
    )

    (1,936,856
    )

    Maturity and sales of available-for-sale securities

    2,002,112

    1,868,482

    923,224

    Purchase of intangible assets

    (10,000
    )

    (11,239
    )

    (1,427
    )

    Acquisition of strategic investments

    —

    (4,000
    )

    (1,000
    )

    Proceeds from sale of Priority Review Voucher

    —

    102,000

    —

    Net cash provided by (used in) investing activities

    755,561

    (165,803
    )

    (1,046,883
    )

    Cash flows from financing activities:

    Settlement of capped call share options for 2024 Notes

    45,349

    80,645

    26,317

    Proceeds from exercise of stock options and purchase of stock under the     Employee Stock Purchase Program

    79,525

    51,246

    30,043

    Payment on maturity of 2024 Notes

    (68
    )

    —

    —

    Debt conversion costs for 2024